{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-100537","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.630683+00:00","generated_at":"2026-05-17T03:13:19.408382+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem partner reports 41% ORR for VS-7375 in heavily pre-treated KRAS G12D PDAC at ESMO 2025","bullets":["ORR of 41% (24/59) in heavily pre-treated advanced KRAS G12D PDAC at 600 mg daily; DCR 96.7%.","Month-four OS rate 92.2%, median OS not reached; median PFS 5.52 months, 4-month PFS rate 78.2%.","91.5% of patients had tumor reduction; 47% still on treatment; longest treatment >1 year.","Safety: 30.3% Grade 3 TRAEs, 3% discontinuation due to TRAEs, no TRAE-related deaths; mean dose intensity 93%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-100537","json":"https://secwatch.observer/filing/0001104659-25-100537.json","markdown":"https://secwatch.observer/filing/0001104659-25-100537.md","text":"https://secwatch.observer/filing/0001104659-25-100537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/0001104659-25-100537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/tm2529024d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:13:19.408382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}